Abstract There has been a recent shift from a uniform treatment targeting HbA1c to a patient centered approach due to disappointing results of intensified glucose control in megatrials such as VADT, ADVANCE, and ACCORD. In addition, morbidity and mortality has been substantially reduced since the UKPDS leading to an overestimation of the absolute risk for cardiovascular complications in randomized controlled trials. With substantial progress in prevention of cardiovascular complications, patients with type 2 diabetes now survive long enough to face diabetes-related complications and cancer risk. This requires rethinking of antidiabetic treatment strategies as exemplified by a recent consensus statement of the EASD and ADA, calling for a more patient centered treatment. Within this context the value of early insulin initiation was reinforced, the clinical utility of which has been demonstrated in the recent ORIGIN trial. ORIGIN demonstrated neutral results for the primary endpoint, but reduced microangiopathy in patients with an HbA1c value of ≥6.4 % with basal insulin glargine. After 5 years of follow-up 77 % of the patients in the glargine arm and 66 % with standard care remained at an HbA1c <7 %. An ongoing long-term followup (ORIGINALE) will clarify whether this also translates into a reduction of macrovascular events and mortality.
Introduction
We face a substantial change in the treatment of type 2 diabetes mellitus based on the results of recent clinical trials and the advent of new treatment options such as incretins and SGLT-2 inhibitors. Further treatment options are under clinical development and new treatment strategies are being tested. These taken all together may result in antidiabetic treatment being more effective and safe in the future than before.
Within this concise review we aim to explain how antidiabetic pharmacotherapy has refocused in recent years leading to trials such as ORIGIN (Outcome Reduction with Initial Glargine Intervention) [1••] which was, 90 years after the introduction of insulin as a life-saving treatment in type 1 diabetes, the first to evaluate the effect of early treatment with basal insulin compared with standard treatment in a large multinational multi-center randomized trial of patients with pre-diabetes and early type 2 diabetes on high cardiovascular risk.
Glucose Centered Randomized Clinical Trials
VADT [2] , ADVANCE [3] , and ACCORD [4] , started early this century, shared the common goal of improving cardiovascular outcomes by means of improved HbA1c control. Diabetes related complications and safety including cancer risk were secondary endpoints. Compared with the UKPDS where treatment was initiated early (in newly diagnosed patients), the patient populations in VADT and ACCORD had treatment that was intensified late in the course of disease after many years of poor control. Results of the more recent trials were largely disappointing: In the VADT [2] intensive glucose control in patients with poorly controlled type 2 diabetes had no significant effect on the rates of major cardiovascular events, death, or microvascular complications. In ADVANCE [3] intensive glucose control that lowered HbA1c to 6.5 % yielded a 10 % relative reduction in the combined outcome of major macrovascular and microvascular events (non-significant). The risk reduction in ADVANCE was mainly driven by a 21 % relative reduction in nephropathy which corresponded to a reduced progression of albuminuria in VADT (P=0.01). In AC-CORD [4] cardiovascular mortality even increased in the intensified treatment arm by 21 % (HR 1.21; 95%CI 1.02-1.44) which led to the premature halt of this trial [4] . Using the cause of mortality in the ACCORD study [4] (Table 1) as an example, it is evident that myocardial infarction whose reduction was a primary treatment objective has a less important quantitative role than cancer and other noncardiovascular diseases which are 2-3 times more frequent. Moreover, in sensitivity analyses, the incidence of myocardial infarction was not reduced with intensive glucose control. This is in contrast to a recent meta-analysis of 5 prospective randomized controlled trials published by Ray in which a 17 % reduction of non-fatal infarcts was observed in favor of an intensified treatment regimen (OR 0.83; 95%CI 0.75-0.93) [5] , while total mortality was equal (OR 1.02; 95%CI 0.87-1. 19 ).
In all of these studies hypoglycemia was an important treatment related complication, in particular with intensified glucose control (OR 2-3; Table 2 ). Authors however were not able to demonstrate a direct link between hypoglycemia and cardiovascular complications in this multimorbid patient population overall [6, 7] . Subsequent analyses showed that there are subgroups within the overall heterogenous, multimorbid study population in which a high mortality rate was associated with a high risk of hypoglycemia [6] . In a recently published prospective study that took into account the heterogeneity of the clinical series by using the Charlson Comorbidity Index it was demonstrated that anamnestic severe hypoglycemia was the most important predictor of cardiovascular and total mortality with an OR of 3.4 (95%CI 1.5-7.4) [8] .
The disappointing results of these glucocentric large randomized trials led to a critical re-evaluation of the benefits and risks of blood glucose lowering drugs. Furthermore it led to the recognition that, based on more recent epidemiological longitudinal studies, morbidity and mortality has substantially changed since the UKPDS leading to an overestimation of the true risk for cardiovascular complications. This appears to be the result of improved blood pressure control, the frequent use of statins, the abundant use of blockers of the reninangiotensin system, and new treatment options for antithrombotic treatment and anticoagulation. The benefits of a treatment effective in controlling cholesterol and blood pressure despite an HbA1c>7 % have impressively been shown in the Steno-2 Study [9, 10] . Furthermore there is substantial improvement of glycemic control in the majority of patients in most countries. For example the mean HbA1c in Germany is 7 % [11, 12] . On the other hand patients with diabetes now survive long enough to face diabetes-related complications and increased risk of cancer.
Patient Centered Treatment
As a result of the disappointing results of a guideline compliant treatment in mega-trials and based on the recognition of the aforementioned change in patient profiles and expectations the "Consensus statement on patient centered treatment" developed by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) was a logical and overdue step towards a rational treatment that also considers clinical heterogeneity. This is especially true for a risk-adjusted intervention that takes into account the comorbidities, risks of hypoglycemia, and remaining life expectancy of vulnerable patients [13] . Derived from this, individualized treatment goals for HbA1c and the intensity of glycemic control were proposed.
It was since the UKPDS trial results became available that metformin became the first-line drug for the treatment of type 2 diabetic patients in international guidelines [5, [14] [15] [16] . Accordingly metformin is recommended in the consensus statement as the drug of choice at the diagnosis of diabetes (Fig. 1) . UKPDS was the only relevant outcome study to compare 3 different treatment options: metformin, sulfonylurea, and insulin. After 11 years of follow-up there was a significant reduction of microvascular complications (9):818-28 [4] in type 2 diabetic patients newly diagnosed at the time of enrollment. Cardiovascular events and total mortality was reduced in the metformin arm while HbA1c was not statistically different at the end of the treatment phase [17, 18] . When 2-drug combinations are necessary the consensus statement leaves it up to the treating physician to select from sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, and (usually basal) insulin. Since there is no evidence-based outcome data for combination therapies, the decision for 1 of the combinations has to be made individually, based on an assessment of benefits and risks and taking into account expectations and the actual situation of the patient.
Pathophysiologic Rationale for Early Insulin Substitution
Normal fasting glucose homeostasis involves the hormonal regulation of glucose utilization and production (insulin, glucagon) and the filtration and reabsorption of glucose by the kidney [19] .
A deficit of insulin secretion is not only pathognomonic for patients with type 1 but also type 2 diabetes. Delayed and defective insulin secretion in type 2 diabetes coupled with defects in insulin action and hyperglucagonemia leads to excessive hepatic glucose release and decreased peripheral glucose uptake. The resulting hyperglycemia and the increase of free fatty acids cause a further loss of β-cell function and increased apoptosis (gluco-and lipotoxicity) [20, 21] . Autopsy studies have shown that even before diabetes is diagnosed, more than 40 % of β-cell mass is lost in patients with Impaired Fasting Glucose (IFG) [22] .
The decreased reabsorption of glucose is 1 potential approach to reduce hyperglycemia and in turn insulin resistance and glucose toxicity. The first such agent, phlorizin was already isolated in 1835 and reduced hyperglycemia by non-selective binding to both SGLT-2 and -1 [23, 24] . Phlorizin normalized insulin sensitivity in diabetic rats (Rossetti et al 1987) . It resulted in glycosuria, which normalized both fasting and fed plasma glucose levels and completely reversed insulin resistance. Upon discontinuation hyperglycemia and insulin resistance recurred. These data demonstrated that hyperglycemia alone can lead to the development of insulin resistance via glucose toxicity [25] . Its development into an antidiabetic drug was later abandoned in favor of more selective SGLT2 inhibitors.
It is well known that in patients with type 1 diabetes a "honeymoon" can be observed after the introduction of effective insulin treatment which is accompanied by an improved residual β-cell function. Thus, the question arose whether the correction of gluco-and lipotoxicity with insulin recovers β-cell function, despite the loss already established with respect to β-cell mass. From earlier in vitro studies it is known that hyperglycemia leads to increased production of free radicals that inhibit the expression of insulin genes in glucotoxic β-cells. This glucotoxic effect develops along a continuum starting in the pre-diabetic range (IFG) and reversible by near normal glucose control. A very important finding was that the recovery of β-cell function was improved with a shorter glucotoxic exposure time [26, 27] . The term "metabolic memory" today summarizes the complex process of denaturation and glycosylation of functional proteins, in particular of the mitochondrial respiratory chain, leading to persisting damage evoked by prolonged hyperglycemia [28] . Patients had no acute insulin response prior to initiation of CSII. After 14 days of CSII treatment acute insulin response was reestablished and the HOMA-IR was reduced from 8.61 to 3.91. The most remarkable result was that, after 2 years, about 50 % of patients with intermittent insulin treatment were still in remission. The results were the better, the shorter the history of diabetes and the closer to normal the initial glycemic control was.
A large retrospective analysis of the long-term results of early insulin treatment in newly diagnosed type 2 diabetic patients, conducted by Chon et al [31] , demonstrated that initial insulin therapy provided better long-term remissions than initiation with oral antidiabetic drugs. The authors concluded that early insulin therapy improved β-cell function and made long-term control of diabetes easier. Accordingly, in the Canadian [32] and Saxonian guidelines [33] initial insulin treatment is recommended for newly diagnosed type 2 diabetes with an HbA1c>9 %.
Insulin Added to Metformin
According to the consensus statement of the EASD / ADA (Fig. 1) insulin is 1 out of a number of treatment options beyond sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists when metformin monotherapy fails. This is however not common practice and sulfonylureas are often used instead [34] . Insulin is frequently only used when HbA1c rises beyond 7.5 % to 8.0 % despite dual or even triple combinations of antidiabetic treatments. It is regarded to be an ultima ratio "complex insulin treatment strategy" which is usually installed on top of initial oral antidiabetic drug treatment.
As Pennartz et al [35] demonstrated in a recent study in type 2 diabetic patients being inadequately controlled with metformin, early use of basal insulin is associated with a significant improvement in residual β-cell function. In the EARLY observational trial, the use of basal insulin glargine in 1438 patients with maximal dose metformin treatment reduced HbA1c from 8.7 % to 7.4 % within 24 weeks with a low risk for hypoglycemia while weight slightly decreased. Upon multivariable analysis the results were the better, the shorter the history of diabetes and the higher the HbA1c at baseline [36] .
Fonseca et al confirmed these results in a recent metaanalysis demonstrating the benefits of early addition of basal insulin to metformin compared with a prior combination of metformin and a sulfonylurea [37] . Patients on metformin monotherapy and add-on glargine insulin achieved a greater reduction in HbA1c with less severe hypoglycemia and less weight gain compared with those with baseline metformin plus sulfonylurea.
The ORIGIN Study Results

Pro or Con Early Insulin Therapy?
ORIGIN was the first to evaluate the effect of early treatment with basal insulin compared with standard treatment in a multinational, multi-center randomized study [1••] . The study included patients with type 2 diabetes but also 12 % of patients with pre-diabetes ( Table 2) . These were substantially different from those of other recent large RCTs in diabetic patients with respect to diabetes duration and HbA1c and complied with the requirements of an early insulin treatment. According to the inclusion criteria they represented, however, a group of patients with high cardiovascular risk. With 66 % of patients having had a prior major cardiovascular event these patients were rather similar to those of the PROactive study [38] and had an increased risk compared with ADVANCE [3] , AC-CORD [4] , and VADT [2] .
After an average follow-up of 6.2 years about 84 % of patients in the glargine arm were still on treatment. The incidence of cardiovascular events as the primary endpoint and all-cause mortality were similar in both groups (all-cause mortality 2.57 %/year in the glargine and 2.60 % in the control arm) and corresponded well to those observed in the PROactive study (all-cause mortality 2.36 %/year in the pioglitazone and 2.45 % in the placebo arm). This is reassuring given the recent analyses of the FDA looking into MACE rates (CV death, non-fatal MI, or stroke) with insulin degludec (/aspart) and glargine, where an increased event rate was noted with degludec (HR 1.82; 95%CI 1.03-3.19) (FDA 2012). Both in the glargine arm and the 1 treated with standard therapy of ORIGIN HbA1c remained within the range of baseline values. For glargine HbA1c was 6.2 % at the end of follow-up and 6.5 % for standard therapy. As with the UKPDS, HbA1c it reached its minimum after 1 year in either strategy (5.9 % vs 6.2 %) and steadily increased thereafter. Fasting blood glucose in the glargine arm (95 mg/dL or 5.6 mmol) remained in the target range however, indicating a moderate worsening of postprandial blood glucose control [39, 40] .
Microangiopathy as a secondary endpoint was less frequent in the glargine than in the standard therapy arm. Further noteworthy results relate to the risk of cancer and hypoglycemia. The risk of lethal (HR 0.94; 95%CI 0.77-1.15) and nonlethal (HR 1.00; 95%CI 0.88-1.13) cancer was virtually identical in both treatment arms, a result which questions the value of recent registry studies suggesting increased cancer rates with insulin glargine compared with human insulin [41, 42] . From a diabetologist's perspective the low incidence of hypoglycemia with glargine in comparison with incidence rates seen in AC-CORD is important. At an almost identical HbA1c (ORIGIN 6.2 %, ACCORD 6.4 %) severe hypoglycemia was infrequent in the glargine arm of ORIGIN but much more frequent in the intensified treatment arms of ACCORD (3.1 %) and VADT (3.8 %) . This has to be interpreted however on the background of a longer diabetes duration (10 years in ACCORD and 11.5 years in VADT vs 5 yrs in ORIGIN) and high baseline HbA1c values (8.1 % in ACCORD, 9.4 % in VADT vs 6.4 % in ORIGIN) ( Table 2 ). Weight gain was 1.6 kg and moderate compared with ACCORD (+2.0 kg) and VADT (+8.2 kg).
Results from a Patient-Centered Treatment Perspective
From a cardiologist's perspective results are neutral. Patients with history of acute coronary syndrome had an identical outcome compared with those without. This corrects conclusions made based on the long-term results of DIGAMI-2 [43] and the European Heart Survey [44] in patients with acute coronary syndromes undergoing treatment with insulin and in which a higher cardiovascular mortality was observed.
From a diabetologist's perspective ORIGIN was the first trial to demonstrate that an early close to normal glycemic control prevents diabetes progression for more than 5 years by keeping HbA1c within the treatment range of around 6.5 %. This halt of progression was on the other hand neither accomplished in the UKPDS [17] nor ADOPT [45] . With this in mind insulin appears to do better, but its clinical relevance can only be determined based on longer term follow-ups which have already been secured by ORIGINALE (and Legacy Effect). In a re-evaluation of glycemic control in the ORIGIN study, in a multivariate analysis with HbA1c <6.5 % as dependent variable, low HbA1c at baseline, and treatment with glargine were predictors of glycemic control within the target range [38] . For daily practice the study demonstrated, with compliance to insulin therapy of 84 % after 6 years, that basal insulin allows a well-accepted and safe treatment management, guided by fasting blood glucose determination.
Conclusions
The results of studies investigating an early intervention with close to normal glycemic control result in the urgent request for a preventive intervention as early as possible. The effectiveness and sustainability of an early intervention before an increase in HbA1c beyond the target range has been documented in ORIGIN. At HbA1c values between 6.5 and 8 % a significant slowing of the increase in HbA1c was observed in the ORIGIN study with both oral antidiabetic treatment options and Insulin, whereas the increase within the target range was less with insulin than with OADs. A clinically relevant benefit in favor of insulin was found only for microangiopathy within the observation period and at HbA1c values>6.4 %. To demonstrate a potential added value for the reduction of cardiovascular endpoints and mortality requires longer follow-up periods as shown in UKPDS [46] and DCCT [47] legacy analysis.
From a clinical practice perspective we would not be hesitant to recommend early insulin initiation in type 2 diabetic patients with an HbA1c>9 % at diagnosis, patients with a fast increase of HbA1c after diagnosis and new onset symptoms, patients with multiple infections and patients with an HbA1c>7 % despite maximal metformin treatment and diabetes-related complications.
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